Actos (Pioglitazone) Rebound Effects When Stopping: What Clinicians and Patients Need to Know
At a glance
- Drug class / Oral thiazolidinedione (TZD), PPAR-gamma agonist, once daily
- Labeled use / Glycemic control in type 2 diabetes with diet and exercise [1]
- Withdrawal syndrome / Not among the label's listed warnings and precautions [1]
- Taper schedule / No step-down schedule in the Actos label [1]
- Half-life / Pioglitazone 3 to 7 hours; metabolites 16 to 24 hours [1]
- Labeled stop rules / Heart failure: consider stopping or lowering dose; liver injury: interrupt; active bladder cancer: should not be used [1]
Does pioglitazone cause rebound or withdrawal?
The label's warnings and precautions cover heart failure, hypoglycemia, liver effects, bladder cancer, edema, fractures, macular edema and macrovascular outcomes; a withdrawal syndrome is not among them [1]. Pioglitazone lowers glucose by decreasing insulin resistance in the periphery and liver, and it is not an insulin secretagogue [1].What the label says about stopping
Dosing starts at 15 or 30 mg once daily and rises in 15 mg steps to a maximum of 45 mg based on HbA1c [1]. No step-down schedule appears in the label [1].- Heart failure. The boxed warning says Actos can cause or exacerbate congestive heart failure; if it develops, the label says discontinuation or dose reduction must be considered [1]. It is not recommended in symptomatic heart failure, and starting it in established NYHA class III or IV heart failure is contraindicated [1].
- Liver injury. The label says liver tests should be measured promptly in patients with symptoms that may indicate liver injury. If ALT is more than 3 times the upper limit of normal, treatment should be interrupted and the cause investigated, and the label says not to restart if liver injury is confirmed without another explanation [1].
- Active bladder cancer. The label says Actos should not be used [1].
What the label trials show
In 26-week monotherapy trials from a baseline HbA1c of about 10.2%, HbA1c changed by -0.3 points on 15 mg, -0.3 on 30 mg and -0.9 on 45 mg, against a rise of 0.7 on placebo [1]. Edema is dose-related; in a 16-week trial, adding Actos 30 mg to a sulfonylurea produced edema in 12.7% versus 2.1% on placebo, and in a 16-week insulin add-on trial it was 17.6% versus 7.0% [1]. In PROactive, edema was 26.7% with pioglitazone versus 15.3% with placebo [1]. The label says weight gain probably reflects both fluid retention and fat accumulation [1].Frequently asked questions
Does pioglitazone cause withdrawal symptoms?
A withdrawal or rebound syndrome is not among the warnings and precautions listed in the Actos label [1]. Pioglitazone is not an insulin secretagogue; it lowers glucose by decreasing insulin resistance [1].
Does the label require tapering pioglitazone?
No tapering schedule appears in the Actos label. The dosage section covers a start of 15 or 30 mg once daily and 15 mg steps to a maximum of 45 mg [1].
What did the label trials show about blood sugar?
In 26-week monotherapy trials from a baseline HbA1c of about 10.2%, HbA1c changed by -0.3 points on 15 mg, -0.3 on 30 mg and -0.9 on 45 mg, against a rise of 0.7 on placebo [1].
What is pioglitazone approved to treat?
It is labeled only as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes [1]. The Actos label says it should not be used to treat type 1 diabetes or diabetic ketoacidosis [1].
References
- U.S. National Library of Medicine, DailyMed. Actos tablets (Takeda) (pioglitazone) prescribing information. Actos tablets (Takeda) (pioglitazone) label